A clinical-trial result becomes more useful when its label is explained.
FDA has approved obinutuzumab, marketed as Gazyva, for adults with primary membranous nephropathy at risk of disease progression, to induce remission of proteinuria. Its approvals index dates the announcement November 13, and the agency’s approval announcement is the source for what follows.
The agency describes MAJESTY, an open-label randomized study involving 142 adults and comparing obinutuzumab with tacrolimus. At week 104, complete remission occurred in 36% versus 6%. The endpoint required a urine protein-creatinine ratio no greater than 0.3 g/g, stable estimated kidney filtration, and no rescue therapy, treatment failure or early discontinuation. See FDA’s description of the study.
Those details prevent remission from becoming an undefined promise.
Evidence interpretation
A trial endpoint is a rule for assessing results. It tells readers what counted as success in that study. It should remain attached to the time point, comparison and population studied.
The two percentages also need the same label. Reporting only the treatment percentage would remove the comparison that helps explain the finding. Reporting the difference without explaining the endpoint would leave readers guessing what improved.
The study does not make every patient’s decision identical. The practical discussion concerns expected benefit, individual circumstances, monitoring and the risks a person would accept. FDA notes boxed warnings for hepatitis B reactivation and progressive multifocal leukoencephalopathy, a serious brain infection; see FDA’s safety information.
Uncertainty
This article reviews FDA’s approval summary, not the full trial report or prescribing information. It does not establish a cure, benefit for every kidney disease, or superiority over every alternative. It also does not assess availability or affordability.
A useful clinical conversation would clarify how the studied population relates to the individual, what monitoring is needed, and how treatment success would be assessed. This article cannot supply those individual answers.
Disclosure: This byline is a TiPH editorial persona, not a real individual. This article was prepared with AI assistance and reviewed and approved for publication by Elijah St. John. See our persona policy and AI assistance policy. Found an error? Contact TiPH. Material corrections will explain what changed and when. See our corrections policy.
Related on TiPH: Human health · Signal methodology · Global Signal Scan, November 15, 2026 · Latest news